

Product Name: BLZ945 Revision Date: 11/18/2022

### **Product Data Sheet**

### **BLZ945**

Cat. No.: B4899

CAS No.: 953769-46-5
Formula: C20H22N4O3S

M.Wt: 398.48

Synonyms:

Target: Tyrosine Kinase

Pathway: CSF-1R

Storage: Store at -20°C



## Solvent & Solubility

insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL in DMSO

In Vitro

	Mass			
Preparing Stock Solutions	Solvent  Concentration	1mg	5mg	10mg
	1 mM	2.5095 mL	12.5477 mL	25.0954 mL
	5 mM	0.5019 mL	2.5095 mL	5.0191 mL
	10 mM	0.2510 mL	1.2548 mL	2.5095 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Shortsummary	CSF-1R kinase inhibitor	
IC <sub>50</sub> & Target		
	Cell Viability Assay	
	Cell Line:	BMDM cell line
	Preparation method:	The solubility of this compound in DMSO is > 19.9 mg/mL. General tips for
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below - 20 °C for several months.
	Reacting conditions:	6.7 ~ 6700 nM; 96 hrs

	Applications:	In BMDM cell line, BLZ945 specifically inhibited CSF-1-dependent proliferation				
		(EC50 = 67 nM), and reduced CSF-1R phosphorylation.				
	Animal experiment	Animal experiment				
	Animal models:	Female MMTV-PyMT transgenic mice				
	Dosage form:	200 mg/kg; p.o.; q.d., for 16 days				
	Applications:	In female MMTV-PyMT transgenic mice, BLZ945 decreased macrophages in				
In Vivo		tumors and livers, but showed no effect on lung macrophages, circulating				
	2000 - California (1900)	monocytes and tumor cell proliferation.				
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may				
		slightly differ with the theoretical value. This is caused by an experimental				
		system error and it is normal.				

#### **Product Citations**

1. Saha D, Martuza RL, Rabkin SD. "Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune CheckpointBlockade". Cancer Cell. 2017 Aug 14;32(2):253-267.e5.PMID:28810147

See more customer validations on www.apexbt.com.

#### References

- [1]. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19(10):1264-72.
- [2]. Strachan DC, Ruffell B2, Oei Y et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013 Dec 1;2(12):e26968.

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

### **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BOOK TO STATE OF THE STATE

AREXED TO STATE OF THE PARTY OF

APENER POLITICAL LINE OF LANDON

APE BOOK TO THE OWNER OF THE OWNER OWNER OF THE OWNER OWNE

APETER TO THE PROPERTY OF THE PARTY OF THE P

ARE LEVEL TO THE STATE OF THE S